Polypharmacological treatment of type 2 diabetes in daily clinical practice;Polyfarmakologisk behandling af type 2-diabetes i daglig klinisk praksis

Ugeskrift for Laeger

Volumn 164, Issue 45, 2002, Pages 5250-5253

  Kristensen, Jette Kolding ^a   Lauritzen, Torsten ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIGUANIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DIET THERAPY; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRESCRIPTION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; DENMARK; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; REGISTRIES;

EID: 0037020873     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in Type 2 diabetes mellitus: How sweet it is ... or is it? Lancet 1997; 350 (suppl 1): 4-9.
2. Olivarius ND, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes. BMJ 2001; 323: 1-9.
3. Uusitupa M, Siitonen O, Aro A. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged newly diagnosed Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1985; 28: 22-7.
4. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
5. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-12.
6. Pyörala K, Pedersen TR, Kjekshus J, Færgeman O, Olsson AG. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart diasease. Diabetes Care 1997; 20: 614-20.
7. Beck-Nielsen H, Henriksen JE, Hermansen K, Madsen LD, de Fine Olivarius N, Mandrup-Poulsen TR et al. Type 2-diabetes og det metaboliske syndrom - Diagnostik og behandling. Ugeskr Læger 2000; 162 (suppl. 6).
8. Kristensen JK, Sandbæk A, Lauritzen T, Lassen JF, Bro F. Use and validation of public data files for identification of the diabetic population in a Danish county. Dan Med Bull 2001; 48: 33-7.
9. Kristensen JK. Identification of the Type 2 Diabetes Population in a Danish County and Evaluation of the Performed Care in a Five-Year Periode [ph.d. afhandling]. Århus: Aarhus Universitet, 2000.
10. American Diabetes Association. Standars of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25: s33-s49.
11. The Royal College of General Practitioners. Clinical Guidelines for Type 2 Diabetes. Sheffild: ScHARR, University of Sheffild, 2002.
12. Kristensen JK, Bro F, Sandbæk A, Dahler-Eriksen T, Lassen J, Lauritzen T. The use and level of HbA1c in an unselected population of 4,438 people with Type 2 diabetes in a Danish County. Scand J Prim Health Care 2001; 19: 241-6.
13. Valle T, Kangas T, Koivisto VA. Glycemic control in patients with diabetes in Finland. Diabetes Care 1999; 22: 575-9.
14. Kamien M, Ward AM, Mansfield F. Management of type 2 diabetes in Western Australian metropolitan general practice. DiabetRes Clin Pract 1994; 26: 197-208.
15. Wright A, Burden ACF, Paisey RB, Cull CA, Holma RR. Sulfonylurea inadequacy (UKPDS 57). Diabetes Care 2002; 25: 330-6.
16. Bouma M, Dekker JH, van Eijk JT. Metabolic control and morbidity of Type 2 diabetic patients in a general practice network. Family Practice 1999; 16: 402-6.
17. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: Proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24 (suppl 3): s6-11.